Bayer tries to revive patent term extension for contraceptive drug

Intellectual Property 2022-03-03 10:00 pm By Cat Fredenburgh | Melbourne

Bayer says the patents office was wrong to quash an extension for its patent covering an oral contraceptive on the grounds that its application should have been based on a drug with an earlier approval date.